Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
18 March 2021 | Story Leonie Bolleurs
Famelab
Abdullahi Jamiu, who is working on his master's degree in Microbiology, was adjudicated as the FameLab winner at the Central Regional Heat and will represent the region at the national semi-finals.

Abdullahi Jamiu, who is working on his master's degree in Microbiology in the Department of Microbiology and Biochemistry at the University of the Free State (UFS), was recently announced as the FameLab winner at the Central Regional Heat and will represent the region at the national semi-finals.

Abdullahi, who plans on pursuing a doctoral degree after his master’s, says he wants to establish himself as an academic in microbiology.

Making science simple
He says he decided to participate in the FameLab competition because he is very passionate about communicating science. “Science communication affords me the opportunity to not only take my research outside of the lab space, but also to communicate it to the lay audience. Moreover, science is often perceived by the general public as difficult and unfathomable. As such, science communication programmes promote the simplification and better understanding of scientific knowledge in the community,” he says.

FameLab is coordinated by the South African Agency for Science and Technology Advancement, the British Council, and Jive Media Africa.

According to Abdullahi, the experience was mind-blowing. “It gave me the opportunity to compress my 200-page master's thesis into a three-minute talk in a way I had never thought was possible. Having to present virtually and adjust to the ‘new normal’ was quite challenging,” he adds.

“The overall experience was enlightening and engaging, and at the same time entertaining,” says Abdullahi.

Impressing the judges with his charisma, engagement with the audience, and use of props, Abdullahi’s presentation focused on how the exploration and exploitation of a ‘combination therapy’ approach to drug discovery could help to effectively combat fungal infections, which are the common comorbidities in immune-compromised individuals, including those living with HIV, cancer, and COVID-19.

Revealing an enigma
His fascination with microbiology started at a young age. “How very tiny, microscopic creatures, invisible to the unaided eye, are able to infect and sometimes kill both healthy and immune-compromised individuals, was an enigma to me as a little boy. My desire to unravel this mystery triggered my interest in microbiology, and the more I learn, the more enthusiastic I become to broaden my horizon in this challenging yet exciting field of study,” he says.

Abdullahi would like to one day make a difference by conducting relevant research aimed at contributing to finding lasting solutions to the lingering menace posed by pathogenic microbes. “Moreover, I am very passionate about facilitating the transfer of scientific knowledge to the next generation,” Abdullahi concludes.

News Archive

New research informs improved treatment of brain inflammation
2017-10-13

Description: Sebolai and Ogundeji Tags: Microbiologist, Dr Adepemi Ogundeji,  

Dr Adepemi Ogundeji, researcher in the Department of Microbial,
Biochemical and Food Biotechnology at the
University of the Free State,
and Dr Olihile Sebolai,
her study leader from the same department.
Photo: Charl Devenish



Microbiologist Dr Adepemi Ogundeji has uncovered a new use for an old medicine that can potentially save lives and money. Under the guidance of her study leader, Dr Olihile Sebolai, Dr Ogundeji set out to fight a fungal disease caused by Cryptococcus neoformans. Drs Ogundeji and Sebolai are from the University of the Free State Department of Microbial, Biochemical and Food Biotechnology. 

Dr Ogundeji is passionate about education. “My aim will always be to transfer knowledge and skills in the microbiology field,” she said. “Dr Ogundeji’s study is celebrated in that it found a new purpose for existing medicines. An advantage of repositioning old medicines is by-passing clinical trials, which sometimes take 20 years, and the safety of such medicines is already known,” Dr Sebolai, explained.

Cryptococcus infections are difficult to control and often lead to brain inflammation. In layman’s terms: “Your brain is on fire”. People with HIV/Aids are especially vulnerable, surviving only about three months without treatment. Such patients may present with a Cryptococcus-emergent psychosis, and some with an out-of-control inflammatory condition when initiated on ARVs. 

Dr Ogundeji found that the clinically recommended dosage of aspirin (anti-inflammatory medicine), and quetiapine (anti-psychotic medicine) is sufficient to control the infection. Her exceptional work was readily published in some of the foremost journals in her field, namely, Antimicrobial Agents and Chemotherapy and Frontiers in Microbiology

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept